Updates

  • September 13, 2013: BioPharm America Conference

    Thomas Hatch, Beech Tree's head of business development, is giving a presentation on BTL-tml for treatment of recurrent oral herpes at the BioPharm America 2013 Conference in Boston September 19th, 2013.  The presentation will include a report of the results of the Company's phase 2a study from 2012, outline the phase 2b study that is currently under way and will detail the Company's plans for further clinical development and eventual commercialization of BTL-tml.  Beech Tree is actively seeking a partner to further develop BTL-tml.

  • July 10, 2013: IND Phase 2b Oral Herpes Trial Begins

    Beech Tree Labs has initiated an IND Phase 2b trial for recurrent oral herpes. This follows a successful Phase 1/2a trial which demonstrated efficacy and safety of BTL-TML-HSV for treating recurrent symptomatic oral herpes virus infection following a dental procedure. This Phase 2b, 100 patient trial will evaluate this agent’s ability to abort lesion appearance from UV-induced cold sores when initiated at the time when itching, burning, and/or rash (prodrome) occur.

  • June 28, 2013: John Ross Joins Board of Directors

    Beech Tree Labs is pleased to announce the appointment of John Ross to the Board of Directors. Spanning a 42-year career, Mr. Ross held senior management and executive level positions in sales, marketing, and market access strategies with medical technology companies such as Baxter, Biomet, Medtronic and Kinetic Concepts. More information on Mr. Ross and our Board of Directors may be found at Board of Directors.

Copyright Beech Tree Labs, Inc.